Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

What this study is testing ClinicalTrials.gov NCT05501483 ↗

Description as written by the study sponsor.

People with newly diagnosed type 2 diabetes treated with metformin that have not reached their HbA1c target (42-64 mmol/mol) will be recruited to the study. If they fulfill the inclusion and none of the exclusion criteria, they will be, after signing informed consent, randomized to a six-month intervention with either pioglitazone, empagliflozin or semaglutide. Fat biopsies are obtained from the subcutaneous abdominal area before and after a hyperinsulinemic-euglycemic clamp at baseline and after six months. Participants are regularly followed during this the intervention. The overall goal is to determine how antidiabetic-drugs affect white adipose tissue cellularity and whether adipose heterogeneity impacts on drug response. The primary outcome measure is the change in fat tissue lipolysis (glycerol release in isolated fat cells after hormone stimulation) before and after treatment.

Treatments tested

• Pioglitazone 45 mg Drug

  Starts with 45 mg

• Empagliflozin 25 MG Drug

  Starts with 25 mg

• Semaglutide 7 MG Drug

  Starts with 3 mg daily for the first 2 weeks